{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:36:43Z","timestamp":1775065003207,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2BX004183"],"award-info":[{"award-number":["IK2BX004183"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX006247"],"award-info":[{"award-number":["I01BX006247"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007928","name":"Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI045008"],"award-info":[{"award-number":["P30 AI045008"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016520"],"award-info":[{"award-number":["P30 CA016520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ymthe.2026.01.007","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T16:07:30Z","timestamp":1768061250000},"page":"2189-2200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-chain IL-23 secretion by CAR-T cells improves tumor control and persistence against solid tumors"],"prefix":"10.1016","volume":"34","author":[{"given":"John T.","family":"Keane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Degaramo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather M.","family":"Sosnoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawna K.","family":"Brookens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon-Gyu S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Avery D.","family":"Posey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.01.007_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.007_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.007_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ymthe.2026.01.007_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/biom10050666","article-title":"The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors","volume":"10","author":"Koustas","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2026.01.007_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T Cell Performance: How to Improve Their Persistence?","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.007_bib10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib11","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41417-023-00642-x","article-title":"CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process","volume":"30","author":"Altvater","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2026.01.007_bib12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib13","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.str.2024.07.010","article-title":"Structure and assembly of the human IL-12 signaling complex","volume":"32","author":"Chen","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.ymthe.2026.01.007_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.01.007_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The Immunobiology of the Interleukin-12 Family: Room for Discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.01.007_bib16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.01.007_bib17","doi-asserted-by":"crossref","first-page":"14002","DOI":"10.1073\/pnas.93.24.14002","article-title":"A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits","volume":"93","author":"Presky","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.01.007_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/abbi.1999.1302","article-title":"Direct interaction of STAT4 with the IL-12 receptor","volume":"368","author":"Yao","year":"1999","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ymthe.2026.01.007_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.0105-2896.2004.00211.x","article-title":"Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4","volume":"202","author":"Watford","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.01.007_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/1573395054065115","article-title":"Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression","volume":"1","author":"Liu","year":"2005","journal-title":"Curr. Immunol. Rev."},{"key":"10.1016\/j.ymthe.2026.01.007_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity","volume":"8","author":"Kueberuwa","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2026.01.007_bib22","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","article-title":"Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.01.007_bib23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","article-title":"IL12 integrated into the CAR exodomain converts CD8","volume":"30","author":"Hombach","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.01.007_bib24","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.01.007_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952231","article-title":"IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003633","article-title":"Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors","volume":"10","author":"Hu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.01.007_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8075","article-title":"Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy","volume":"8","author":"Jones","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.01.007_bib28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/jimmunol.1800033","article-title":"Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma","volume":"203","author":"Liu","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib29","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41467-023-37646-y","article-title":"Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models","volume":"14","author":"Yang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.01.007_bib30","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-019-12006-x","article-title":"The molecular basis of chaperone-mediated interleukin 23 assembly control","volume":"10","author":"Meier","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.01.007_bib31","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.01.007_bib32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.01.007_bib33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves CAR T cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.007_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.01.007_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.01.007_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-beta induces development of the T(H)17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.01.007_bib38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.01.007_bib39","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1016\/j.cell.2021.11.018","article-title":"Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity","volume":"184","author":"Schnell","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.01.007_bib40","doi-asserted-by":"crossref","first-page":"11482","DOI":"10.1073\/pnas.1705536114","article-title":"Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-gamma","volume":"114","author":"Kundu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.01.007_bib41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/eji.1830250133","article-title":"Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist","volume":"25","author":"Gillessen","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib42","doi-asserted-by":"crossref","first-page":"36012","DOI":"10.1074\/jbc.M112.390625","article-title":"Novel IL27p28\/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1\/Th17 cells and promoting expansion of regulatory T cells","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.01.007_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41423-021-00798-2","article-title":"A novel cytokine consisting of the p40 and EBI3 subunits suppresses experimental autoimmune arthritis via reciprocal regulation of Th17 and Treg cells","volume":"19","author":"Lee","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib44","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.01.007_bib45","article-title":"(in press). CD2 costimulation bridges potent CAR-induced cytolysis and durable persistence","volume":"013208","author":"Liu","year":"2026","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.ymthe.2026.01.007_bib46","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.01.007_bib47","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.immuni.2018.02.010","article-title":"Understanding Subset Diversity in T Cell Memory","volume":"48","author":"Jameson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.01.007_bib48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.01.007_bib49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.01.007_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ymthe.2026.01.007_bib51","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1172\/JCI36389","article-title":"Evidence that cytokines play a role in rheumatoid arthritis","volume":"118","author":"Brennan","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.01.007_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41927-017-0001-8","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets","volume":"1","author":"Alunno","year":"2017","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: from bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.01.007_bib54","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.01.007_bib55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.01.007_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2026.01.007_bib57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib58","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.01.007_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.01.007_bib60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.01.007_bib61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2022.07.004","article-title":"TCF1(+)PD-1(+) tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer","volume":"174","author":"Koh","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.01.007_bib62","unstructured":"M.S.K.C. Center. (2015). NCT02498912: Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients with Recurrent MUC16ecto+ Solid Tumors."},{"key":"10.1016\/j.ymthe.2026.01.007_bib63","unstructured":"R.P.C. Institute. (2024). NCT06343376: Genetically Engineered Cells (EGFRt\/19-28z\/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies."},{"key":"10.1016\/j.ymthe.2026.01.007_bib64","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1111\/cas.15374","article-title":"IL-27 improves adoptive CD8","volume":"113","author":"Ding","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ymthe.2026.01.007_bib65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-immunol-032414-112134","article-title":"The immunobiology of interleukin-27","volume":"33","author":"Yoshida","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib66","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib67","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.01.007_bib68","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.01.007_bib69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ymthe.2026.01.007_bib70","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.01.007_bib71","doi-asserted-by":"crossref","first-page":"W83","DOI":"10.1093\/nar\/gkae410","article-title":"The Galaxy platform for accessible, reproducible, and collaborative data analyses: 2024 update","volume":"52","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.01.007_bib72","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng0506-500","article-title":"GenePattern 2.0","volume":"38","author":"Reich","year":"2006","journal-title":"Nat. Genet."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:33:41Z","timestamp":1775057621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1525001626000080"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.01.007","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-chain IL-23 secretion by CAR-T cells improves tumor control and persistence against solid tumors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}